{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:34Z","timestamp":1786985434228,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.bmcl.2015.05.065","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T03:03:18Z","timestamp":1432868598000},"page":"3275-3280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Design, synthesis and evaluation of MCH receptor 1 antagonists\u2014Part III: Discovery of pre-clinical development candidate BI 186908"],"prefix":"10.1016","volume":"25","author":[{"given":"Thorsten","family":"Oost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Heckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg T.","family":"Kley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Rudolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Budzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf R.H.","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd-Michael","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Markert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Stenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2015.05.065_b0005","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/13543776.2011.575063","volume":"21","author":"Johannson","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bmcl.2015.05.065_b0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14740338.5.4.567","volume":"5","author":"Reasor","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bmcl.2015.05.065_b0015","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.drudis.2007.08.010","volume":"12","author":"M\u00e9ndez-Andino","year":"2007","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bmcl.2015.05.065_b0020","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1016\/j.bmcl.2012.08.025","volume":"22","author":"H\u00f6gberg","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2015.05.065_b0025","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1016\/j.bmcl.2015.05.074","volume":"25","author":"Roth","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2015.05.065_b0030","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1016\/j.bmcl.2015.05.077","volume":"25","author":"M\u00fcller","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2015.05.065_b0035","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1016\/j.bmcl.2009.07.023","volume":"19","author":"Ando","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmcl.2015.05.065_h0040","unstructured":"Oost, T.; Lotz, R.; Stenkamp, D. WO13131935, 2013"},{"key":"10.1016\/j.bmcl.2015.05.065_h0045","unstructured":"Stenkamp, D. et al. WO09103478, 2009"},{"key":"10.1016\/j.bmcl.2015.05.065_h0050","unstructured":"Stenkamp, D. et al. WO08022979, 2008"},{"key":"10.1016\/j.bmcl.2015.05.065_h0055","unstructured":"MCH-R1 binding assay: Membranes from CHO\/Galpha16 cells stably transfected with human MCH-R1 are re-suspended using a syringe (needle 0.6\u00d725mm) and diluted in test buffer (50mM HEPES, 10mM MgCl2, 2mM EGTA, pH 7.00; 0.1% bovine serum albumin (protease-free), 0.021% bacitracin, 1\u03bcg\/ml aprotinin, 1\u03bcg\/ml leupeptin and 1\u03bcM phosphoramidone) to a concentration of 5\u201315\u03bcg\/ml. 200\u03bcL of this membrane fraction (contains 1\u20133\u03bcg of protein) are incubated for 60min at ambient temperature with 100pM of 125I-tyrosyl melanin concentrating hormone (125I-MCH commercially obtainable from NEN) and increasing concentrations of the test compound in a final volume of 250\u03bcL. After the incubation the reaction is filtered using a cell harvester through 0.5% PEI treated fibreglass filters (GF\/B, Unifilter Packard). The membrane-bound radioactivity retained on the filter is then determined after the addition of scintillator substance (Packard Microscint 20) in a measuring device (TopCount of Packard). The non-specific binding is defined as bound radioactivity in the presence of 1\u03bcM MCH during the incubation period. The analysis of the concentration binding curve is carried out on the assumption of one receptor binding site. IC50 values are the mean of at least two separately performed experiments. Standard: Non-labelled MCH competes with labelled 125I-MCH for the receptor binding with an IC50 value of 0.06\u20130.15nM. The KD value of the radioligand is 0.16nM"},{"key":"10.1016\/j.bmcl.2015.05.065_h0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0021-9673(02)00064-X","volume":"952","author":"Donovan","year":"2002","journal-title":"J. Chromatogr., A"},{"key":"10.1016\/j.bmcl.2015.05.065_h0065","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0006-2952(97)82443-4","volume":"53","author":"Xia","year":"1997","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.bmcl.2015.05.065_h0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1024778329320","volume":"19","author":"Casartelli","year":"2003","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.bmcl.2015.05.065_b0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vascn.2011.05.002","volume":"64","author":"Markert","year":"2011","journal-title":"J. Pharmacol. Toxicol."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X15005399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X15005399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:03:34Z","timestamp":1760771014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X15005399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":15,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0960894X15005399"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2015.05.065","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and evaluation of MCH receptor 1 antagonists\u2014Part III: Discovery of pre-clinical development candidate BI 186908","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2015.05.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}